Browse Items · NEOMED Bibliography Database

Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease.

A series of compounds related to piperine and antiepilepsirine was screened in a monoamine oxidase A and B assay. Piperine is an alkaloid from the source plant of both black and white pepper grains, Piper nigrum. Piperine has been shown to have a…

Markers associated with testosterone enhancement of methamphetamine-induced striatal dopaminergic neurotoxicity.

Intact male CD-1 mice received an injection of testosterone propionate (TP–5 ug), progesterone (P–5 mg), the oil vehicle or remained untreated (control). At 24 hours after hormonal treatments the mice received an injection of methamphetamine (MA–40…

Structure-activity relationship and docking studies of thiazolidinedione-type compounds with monoamine oxidase B.

The neuroprotective activity of pioglitazone and rosiglitazone in the MPTP parkinsonian mouse prompted us to evaluate a set of thiazolidinedione (TZD) type compounds for monoamine oxidase A and B inhibition activity. These compounds were able to…

Oxidative stress and Alzheimer's disease: dietary polyphenols as potential therapeutic agents.

Oxidative stress has been strongly implicated in the pathophysiology of neurodegenerative disorders such as Alzheimer's disease (AD). In recent years, antioxidants - especially those of dietary origin - have been suggested as possible agents useful…

Tags: 2010, Alzheimer Disease/*physiopathology/*therapy, Animals, Antioxidants/*administration & dosage/chemistry/pharmacology, Bishayee Anupam, Carroll Richard T, Darvesh Altaf S, Department of Pharmaceutical Sciences, Expert review of neurotherapeutics, Flavonoids/*administration & dosage/chemistry/pharmacology, Geldenhuys Werner J, Humans, Mitochondria/drug effects/physiology, NEOMED College of Pharmacy, Neurodegenerative Diseases/physiopathology, Oxidative Stress/drug effects/*physiology, Phenols/*administration & dosage/chemistry/pharmacology, Polyphenols, Van der Schyf Cornelis J

Curcumin and neurodegenerative diseases: a perspective.

INTRODUCTION: Curcumin, a dietary polyphenol found in the curry spice turmeric, possesses potent antioxidant and anti-inflammatory properties and an ability to modulate multiple targets implicated in the pathogenesis of chronic illness. Curcumin has…

Tags: 2012, Animals, Bishayee Anupam, Carroll Richard T, Curcumin/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use, Darvesh Altaf S, Department of Pharmaceutical Sciences, Drug Evaluation, Expert opinion on investigational drugs, Geldenhuys Werner J, Humans, NEOMED College of Pharmacy, Neurodegenerative Diseases/*drug therapy/metabolism, Neuroprotective Agents/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use, Novotny Nicholas A, Oxidative Stress/drug effects, Preclinical, Van der Schyf Cornelis J

In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

INTRODUCTION: Microdialysis is an important in vivo sampling technique, useful in the assay of extracellular tissue fluid. The technique has both pre-clinical and clinical applications but is most widely used in neuroscience. The in vivo…

Tags: 2011, Carroll Richard T, Darvesh Altaf S, Department of Pharmaceutical Sciences, Expert opinion on drug discovery, Geldenhuys Werner J, Gudelsky Gary A, Klein Jochen, Meshul Charles K, NEOMED College of Pharmacy, Van der Schyf Cornelis J

4-Hydroxynonenal dependent alteration of TRPV1-mediated coronary microvascular signaling.

We demonstrated previously that TRPV1-dependent regulation of coronary blood flow (CBF) is disrupted in diabetes. Further, we have shown that endothelial TRPV1 is differentially regulated, ultimately leading to the inactivation of TRPV1, when exposed…

Tags: *4-Hydroxynonenal, *Coronary regulation, *Lipid peroxidation, *Post-translational modification, *Protein Processing, *Reactive oxygen species, *Signal Transduction, *TRPV1, 2016, Action Potentials/drug effects, Aldehydes/antagonists & inhibitors/metabolism/*pharmacology, Animal, Animals, Blood Flow Velocity, Bratz Ian N, Calcium Signaling/drug effects, Cappelli Holly C, Capsaicin/*pharmacology, Cardiovascular Agents/*pharmacology, Connell Patrick J, Coronary Circulation/drug effects, Coronary Vessels/metabolism/physiopathology, Cysteine/genetics/metabolism, Damron Derek S, DelloStritto Daniel J, Department of Integrative Medical Sciences, Diabetes Mellitus/drug therapy/*metabolism/physiopathology, Disease Models, Fahmy Joseph N, Femoral Artery/metabolism/physiopathology, Free radical biology & medicine, Geldenhuys Werner J, HEK293 Cells, Humans, Inbred C57BL, Lipid Peroxidation, Male, Mice, NEOMED College of Medicine, Patch-Clamp Techniques, Post-Translational, Sinharoy Pritam, Thodeti Charles K, TRPV Cation Channels/genetics/*metabolism, Vasodilation/drug effects

Parkinson's disease biomarker: a patent evaluation of WO2013153386.

INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative movement disorder resultant from the loss of dopaminergic neurons in the brain. There is an urgent need for effective biomarkers that can be used in the early diagnosis of PD.…

The blood-brain barrier choline transporter.

Drug delivery to the brain is made difficult by the blood-brain barrier (BBB) which is selectively permeable to organic drug compounds. Several membrane solute and nutrient transporters are expressed in the BBB vasculature, which may be utilized as…

Tags: 2012, Allen David D, Animals, Blood-Brain Barrier/drug effects/*metabolism, Central nervous system agents in medicinal chemistry, Drug Delivery Systems/*methods, Geldenhuys Werner J, Humans, Membrane Transport Proteins/*metabolism, Organic Cation Transport Proteins/metabolism, Organic Cation Transporter 1/metabolism, Organic Cation Transporter 2

Novel models for assessing blood-brain barrier drug permeation.

INTRODUCTION: The blood-brain barrier (BBB) is a selectively permeable micro-vascular unit which prevents many central nervous system (CNS)-targeted compounds from reaching the brain. A significant problem in CNS drug development is the ability to…

Tags: *Capillary Permeability, 2012, Allen David D, Animal, Animals, Blood-Brain Barrier/*metabolism, Bloomquist Jeffrey R, Drosophila melanogaster/metabolism, Expert opinion on drug metabolism & toxicology, Geldenhuys Werner J, Grasshoppers/metabolism, High-Throughput Screening Assays, Humans, Models, Pharmaceutical Preparations/*metabolism, Zebrafish/metabolism

3-D-QSAR and docking studies on the neuronal choline transporter.

The high affinity neuronal choline transporter (CHT1) is responsible for the uptake of choline into the pre-synaptic terminal of cholinergic neurons. Considering our past experience with modeling the blood-brain barrier choline transporter (BBBCHT)…

Tags: 2010, Allen David D, Binding Sites, Bioorganic & medicinal chemistry letters, Blood-Brain Barrier/metabolism, Computer Simulation, Geldenhuys Werner J, Lockman Paul R, Membrane Transport Proteins/*chemistry/metabolism, Models, Molecular, Neurons/*metabolism, Quantitative Structure-Activity Relationship, Quaternary Ammonium Compounds/chemistry

A novel Lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4).

Lipoprotein lipase (LPL) is a key physiological regulator of triglycerides and atherosclerosis risk. Random screening identified a compound designated C10, showing greater LPL agonist activity than NO-1886, a known LPL agonist. Structure-activity…

MitoNEET (CISD1) Knockout Mice Show Signs of Striatal Mitochondrial Dysfunction and a Parkinson's Disease Phenotype.

Mitochondrial dysfunction is thought to play a significant role in neurodegeneration observed in Parkinson's disease (PD), yet the mechanisms underlying this pathology remain unclear. Here, we demonstrate that loss of mitoNEET (CISD1), an iron-sulfur…

High-content screen using zebrafish (Danio rerio) embryos identifies a novel kinase activator and inhibitor.

In this report we utilized zebrafish (Danio rerio) embryos in a phenotypical high-content screen (HCS) to identify novel leads in a cancer drug discovery program. We initially validated our HCS model using the flavin adenosine dinucleotide (FAD)…

Tags: *Cancer, *Compound library, *Kinase, *Notochord, *Phenotypic screen, *Somites, *Zebrafish, 2017, Aljammal Rowaa, Animals, Antineoplastic Agents/chemistry/pharmacology, Antitumor/methods, Benzoic Acid/chemistry/pharmacology, Bergeron Sadie A, Bioorganic & medicinal chemistry letters, Chen Wei-Chi, Death-Associated Protein Kinases/metabolism, Department of Integrative Medical Sciences, Drug Discovery/*methods, Drug Screening Assays, Embryo, Enzyme Activation/drug effects, Enzyme Activators/*chemistry/*pharmacology, Gaasch Briah L, Geldenhuys Werner J, Hazlehurst Lori A, Mullins Jackie E, NEOMED College of Medicine, Neoplasms/drug therapy/enzymology, Nonmammalian/*drug effects/enzymology, Protein Kinase Inhibitors/*chemistry/*pharmacology, Protein-Serine-Threonine Kinases/antagonists & inhibitors/metabolism, Yun June, Zebrafish Proteins/antagonists & inhibitors/metabolism, Zebrafish/*embryology

Effects of a novel dopamine uptake inhibitor upon extracellular dopamine from superfused murine striatal tissue.

The dopamine transporter (DAT) plays an important role in substance abuse, schizophrenia, and dopaminergic toxicity associated with the Parkinsonian animal model toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Accordingly, the DAT serves…

Natural products of dietary origin as lead compounds in virtual screening and drug design.

Natural products have been found to be useful in the treatment of several diseases across the ages. In this article, we review the use of natural products, obtained from dietary sources, as lead compounds in developing novel therapeutic agents. These…

Tags: *Biological Products/pharmacology, *Drug Design, 2012, Animals, Bishayee Anupam, Caffeine/pharmacology, Carroll Richard T, Curcumin/pharmacology, Current pharmaceutical biotechnology, Darvesh Altaf S, Department of Pharmaceutical Sciences, Diet, Geldenhuys Werner J, Genistein/pharmacology, Humans, NEOMED College of Pharmacy, Resveratrol, Stilbenes/pharmacology

Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator.

Elevated triglycerides (TG) contribute towards increased risk for cardiovascular disease. Lipoprotein lipase (LPL) is an enzyme that is responsible for the metabolism of core triglycerides of very-low density lipoproteins (VLDL) and chylomicrons in…

Evolution of a Natural Products and Nutraceuticals Course in the Pharmacy Curriculum.

Objective. To develop, implement, and modify a required, second-year pharmacy course that provides an understanding of the scientific, therapeutic, and clinical principles, as well as the evidence-based medicine underlying the use of natural…

Pharmacotherapy of Alzheimer's disease: current and future trends.

Alzheimer's disease (AD) and its related dementia has shown an alarming rise in the global population. Although considerable efforts have been made to develop effective therapeutic agents for AD therapy, drug development has not met significant…

Tags: 2015, Alzheimer Disease/*drug therapy, Alzheimer's disease, Anti-Inflammatory Agents, Antioxidants, cholinesterase inhibitors, Darvesh Altaf S, dementia, Department of Pharmaceutical Sciences, Drug Therapy/*methods/*trends, Expert review of neurotherapeutics, Geldenhuys Werner J, Humans, immunotherapy, memantine, multi-targeted drugs, natural products, NEOMED College of Pharmacy, Pharmacotherapy

Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.

Dimebon is an anti-histamine with central nervous system activity. In this report the effects of dimebon as a neuroprotectant in animal models of Parkinson's disease were tested as assessed in methamphetamine- and MPTP-induced striatal dopaminergic…

Tags: 2012, Animals, Corpus Striatum/*drug effects/metabolism, Darvesh Altaf S, Department of Pharmaceutical Sciences, Dluzen Dean E, Dopamine/*metabolism, Drug Synergism, Geldenhuys Werner J, Inbred C57BL, Indoles/*pharmacology, Methamphetamine/*pharmacology, Mice, NEOMED College of Pharmacy, Neurochemistry international

Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.

Parkinson's disease is a severe debilitating neurodegenerative disorder. Recently, it was shown that the peroxisome proliferating-activator receptor-gamma agonist pioglitazone protected mice from

Tags: 2010, Bioorganic & medicinal chemistry letters, Carroll Richard T, Darvesh Altaf S, Department of Pharmaceutical Sciences, Funk Max O, Geldenhuys Werner J, Models, Molecular, Monoamine Oxidase Inhibitors/chemistry/*pharmacology, Monoamine Oxidase/*drug effects, NEOMED College of Pharmacy, Structure-Activity Relationship, Van der Schyf Cornelis J

A novel binding assay identifies high affinity ligands to the rosiglitazone binding site of mitoNEET.

A novel outer mitochondrial membrane protein containing [2Fe-2S] clusters, mitoNEET was first identified through its binding to the anti-diabetic drug pioglitazone. Pioglitazone belongs to a family of drugs that are peroxisome proliferator-activated…

Tags: 2011, Awale Prabha S, Binding Sites/drug effects, Bioorganic & medicinal chemistry letters, Carroll Richard T, Dose-Response Relationship, Drug, Funk Max O, Geldenhuys Werner J, Ligands, Lin Li, Mitochondrial Proteins/*antagonists & inhibitors/metabolism, Molecular Structure, Recombinant Proteins/antagonists & inhibitors/metabolism, Rosiglitazone, Stereoisomerism, Structure-Activity Relationship, Thiazolidinediones/chemical synthesis/chemistry/*pharmacology

Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET.

Several PPAR-gamma agonists containing a thiazolidinedione moiety (referred to as glitazones) have been proposed to be neuroprotective and appear to alter mitochondrial function. Recently, a search for mitochondrial proteins that bind pioglitazone…

A scaffold hopping approach to identify novel monoamine oxidase B inhibitors.

Monoamine oxidase B (MAO-B) inhibitors are used to treat Parkinson's disease. In this study, we searched for novel MAO-B inhibitors using a scaffold hopping approach based on our experience with the thiazolidinedione (TZD) class of compounds as MAO-B…

Tags: *Monoamine Oxidase/chemistry/metabolism, 2012, Benzofurans/chemistry/pharmacology, Bioorganic & medicinal chemistry letters, Carroll Richard T, Enzyme Activation/drug effects, Flavonoids/chemistry/pharmacology, Funk Max O, Geldenhuys Werner J, Humans, Inhibitory Concentration 50, Models, Molecular, Molecular Structure, Monoamine Oxidase Inhibitors/*chemistry/*pharmacology, Protein Binding/drug effects, Small Molecule Libraries, Structure-Activity Relationship, Van der Schyf Cornelis J

A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease.

Parkinson's disease (PD) is an age-associated neurodegenerative disorder hallmarked by a loss of mesencephalic dopaminergic neurons. Accurate recapitulation of the PD movement phenotype in animal models of the disease is critical for understanding…

Tags: 2015, Behavior, Department of Anatomy & Neurobiology, Dluzen Dean E, Gait, Geldenhuys Werner J, Gender-bias, Guseman Tamara L, Locomotion, MPTP, NEOMED College of Medicine, PeerJ, Pienaar Ilse S, Young Jesse W

Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases.

Cardiovascular diseases remain the number one diseases affecting patients' morbidity and mortality. The adenosine receptors are G-protein coupled receptors which have been of interest for drugs target for the treatment of multiple diseases ranging…

Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease.

Parkinson's disease (PD) is an age-related neurodegenerative disease affecting movement. To date, there are no currently available therapeutic agents which can prevent or slow disease progression. Here, we evaluated an azobenzene derivative, methyl…

Tags: *MAO-B inhibitor, *methyl yellow, *MPTP mouse model, *Parkinson's disease, *TMRM, 2014, Chembiochem : a European journal of chemical biology, Dluzen Dean E, Geldenhuys Werner J, Kochi Akiko, Lim Mi Hee, Lin Li, Sutariya Vijaykumar, Van der Schyf Cornelis J

Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.

The NK(3) subtype of tachykinin receptor is a G protein-coupled receptor that is a potential therapeutic target for several neurological diseases, including schizophrenia. In this study, we have screened compound databases for novel NK(3) receptor…

mitoNEET as a novel drug target for mitochondrial dysfunction.

Mitochondrial dysfunction plays an important part in the pathology of several diseases, including Alzheimer's disease and Parkinson's disease. Targeting mitochondrial proteins shows promise in treating and attenuating the neurodegeneration seen in…

Tags: 2014, Animals, Carroll Richard T, Drug Delivery Systems, Drug Discovery Today, Energy Metabolism, Geldenhuys Werner J, Humans, Leeper Thomas C, Mitochondria/*metabolism, Mitochondrial Proteins/chemistry/*metabolism, Protein Conformation, Thiazolidinediones/pharmacology

Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Although statins and other pharmacological approaches have improved the management of lipid abnormalities, there exists a need for newer treatment modalities especially for the management of hypertriglyceridemia. Lipoprotein lipase (LPL), by…

Tags: 2017, Animals, Cardiovascular Diseases/drug therapy/*enzymology, Darvesh Altaf S, Department of Pharmaceutical Sciences, Department of Pharmacy Practice, Drug Discovery Today, Geldenhuys Werner J, Humans, Lin Li, Lipoprotein Lipase/chemistry/*metabolism, Metabolic Diseases/drug therapy/*enzymology, NEOMED College of Graduate Studies, NEOMED College of Pharmacy, Sadana Prabodh

Structure-activity relationships of pentacycloundecylamines at the

Prompted by our interest in neuroprotective agents with multiple mechanisms of action, we assessed the structure-activity relationship of a series of pentacycloundecylamine derivatives previously shown to have both L-type calcium channel blocking…

Molecular determinants of blood-brain barrier permeation.

The blood-brain barrier (BBB) is a microvascular unit which selectively regulates the permeability of drugs to the brain. With the rise in CNS drug targets and diseases, there is a need to be able to accurately predict a priori which compounds in a…

Tags: *Drug Delivery Systems, 2015, Adkins Chris E, Animals, Blood-Brain Barrier/*metabolism, Brain/drug effects, Computer Simulation, Geldenhuys Werner J, high-throughput, Humans, in silico, Lockman Paul R, logPS, Mohammad Afroz S, nutrient transporters, Permeability, Therapeutic delivery, Virtual screening

3D-QSAR and docking studies on transforming growth factor (TGF)-beta receptor 1 antagonists.

The transforming growth factor-beta (TGF-beta) is part of a family of cytokines which regulate various signaling pathways such as cell development, growth, and tissue injury. Although several studies have been published describing the synthesis of…

Tags: 2010, Bioorganic & medicinal chemistry letters, Geldenhuys Werner J, Models, Molecular, Nakamura Hiroshi, Quantitative Structure-Activity Relationship, Receptors, Transforming Growth Factor beta/*antagonists & inhibitors

3D-QSAR and docking studies of pentacycloundecylamines at the sigma-1 (sigma1) receptor.

Pentacycloundecylamine (PCU) derived compounds have been shown to be promising lead structures for the development of novel drug candidates aimed at a variety of neurodegenerative and psychiatric diseases. Here we show for the first time a 3D…

Tags: *Quantitative Structure-Activity Relationship, 2013, Amines/*chemistry/metabolism, Aza Compounds/chemistry, Binding Sites, Bioorganic & medicinal chemistry letters, Geldenhuys Werner J, Kinetics, Malan Sarel F, Molecular Docking Simulation, Novotny Nicholas, Protein Binding, Protein Structure, Receptors, sigma/*chemistry/metabolism, Tertiary, Van der Schyf Cornelis J

3D-Quantitative structure-activity relationship and docking studies of the tachykinin NK3 receptor.

The tachykinin NK(3) receptor (NK(3)R) is a novel drug target for schizophrenia and drug abuse. Since few non-peptide antagonists of this G protein-coupled receptor are available, we have initiated this study to gain a better understanding of the…

Tags: *Quantitative Structure-Activity Relationship, 2011, Binding Sites, Bioorganic & medicinal chemistry letters, Computer Simulation, Drug Design, Geldenhuys Werner J, Humans, Ligands, Models, Molecular, Neurokinin-3/*chemistry/metabolism, Protein Structure, Quinolines/chemistry, Receptors, Simmons Mark A, Tertiary

Identification of a novel serum and glucocorticoid regulated kinase-1 (SGK1) ligand from virtual screening.

The serum and glucocorticoid regulated kinase-1 (SGK1) is part of the serine/threonine kinase family and has therapeutic potential in several neurodegenerative diseases such as ischemic stroke and Parkinson's disease. Here we use structure-based…

Tags: 2012, Binding Sites, Bioorganic & medicinal chemistry letters, Department of Pharmaceutical Sciences, Department of Pharmacy Practice, Drug Discovery, Geldenhuys Werner J, Humans, Immediate-Early Proteins/*antagonists & inhibitors/chemistry/metabolism, Ligands, Molecular Docking Simulation, NEOMED College of Graduate Studies, NEOMED College of Pharmacy, Protein Kinase Inhibitors/*chemistry/*pharmacology, Protein-Serine-Threonine Kinases/*antagonists & inhibitors/chemistry/metabolism, Sadana Prabodh, Talasila Phani K

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.

INTRODUCTION: Neurodegenerative diseases have had devastating effects on patients' quality of life. These complex diseases have several pathways that are affected to initiate cell death. Current therapies, designed to address only a single target,…

Tags: *Drug Design, 2013, Central Nervous System Diseases/*drug therapy, Clinical Trials as Topic, Expert opinion on drug discovery, Geldenhuys Werner J, Humans, Neurodegenerative Diseases/*drug therapy, Neuroprotective Agents/*chemistry/therapeutic use, Van der Schyf Cornelis J

The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease.

The serotonin 6 receptor is attracting attention as an etiological contributor in cognition deficits in diseases such as Alzheimer's disease, anxiety/depression and schizophrenia. In this review, we discuss the role of this recently discovered G…

Tags: 2009, Alzheimer Disease/*complications, Animals, Biological, Cognition Disorders/*drug therapy/*etiology, Drug Design, Expert review of neurotherapeutics, Geldenhuys Werner J, Humans, Models, Receptors, Serotonin Antagonists/chemistry/*therapeutic use, Serotonin/*metabolism, Structure-Activity Relationship, Van der Schyf Cornelis J

Role of serotonin in Alzheimer's disease: a new therapeutic target?

Mounting evidence accumulated over the past few years indicates that the neurotransmitter serotonin plays a significant role in cognition. As a drug target, serotonin receptors have received notable attention due in particular to the role of several…

Tags: 2011, Alzheimer Disease/*drug therapy/*metabolism, Alzheimer's Disease – Drug Therapy, Alzheimer's Disease – Metabolism, Animals, Cell Surface – Metabolism, Clinical Trials, Clinical Trials as Topic, CNS drugs, Drug Evaluation, Geldenhuys Werner J, Humans, Preclinical, Receptors, Serotonin – Pharmacodynamics, Serotonin – Therapeutic Use, Serotonin/*metabolism, Serotonin/*pharmacology/*therapeutic use, Van der Schyf Cornelis J

Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.

Recently, the serotonin 5-HT(6) receptor has been identified as a drug target for attenuating cognitive deficits associated with Alzheimer's disease (AD). Additionally, this receptor may also play a role in schizophrenia, anxiety and obesity. Reports…

Tags: 2008, Alzheimer Disease/*drug therapy, Current topics in medicinal chemistry, Geldenhuys Werner J, Humans, Molecular Structure, Nootropic Agents/chemistry/*therapeutic use, Receptors, Serotonin Antagonists/chemistry/*therapeutic use, Serotonin/*metabolism, Van der Schyf Cornelis J

Browse Items (61 total)